ZA908731B - Method for using(2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure - Google Patents

Method for using(2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure

Info

Publication number
ZA908731B
ZA908731B ZA908731A ZA908731A ZA908731B ZA 908731 B ZA908731 B ZA 908731B ZA 908731 A ZA908731 A ZA 908731A ZA 908731 A ZA908731 A ZA 908731A ZA 908731 B ZA908731 B ZA 908731B
Authority
ZA
South Africa
Prior art keywords
alkyl
imidazolin
hydrogen
positions
intraocular pressure
Prior art date
Application number
ZA908731A
Other languages
English (en)
Inventor
Charles Gluchowski
Gluchowski Charles
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA908731B publication Critical patent/ZA908731B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA908731A 1989-10-31 1990-10-15 Method for using(2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure ZA908731B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/429,835 US5021416A (en) 1989-10-31 1989-10-31 Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Publications (1)

Publication Number Publication Date
ZA908731B true ZA908731B (en) 1991-07-31

Family

ID=23704912

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA908731A ZA908731B (en) 1989-10-31 1990-10-15 Method for using(2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure

Country Status (18)

Country Link
US (1) US5021416A (de)
EP (1) EP0426390B1 (de)
JP (1) JP2999240B2 (de)
KR (1) KR910007530A (de)
AT (1) ATE122233T1 (de)
AU (1) AU627626B2 (de)
CA (1) CA2025189A1 (de)
DE (1) DE69019297T2 (de)
ES (1) ES2074138T3 (de)
FI (1) FI905369A0 (de)
HU (1) HU207946B (de)
IE (1) IE68413B1 (de)
IL (1) IL96083A (de)
NZ (1) NZ235884A (de)
PH (1) PH26978A (de)
RU (1) RU1829937C (de)
TW (1) TW218352B (de)
ZA (1) ZA908731B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ES2187533T3 (es) * 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
JPH09506622A (ja) * 1993-12-17 1997-06-30 ザ、プロクター、エンド、ギャンブル、カンパニー α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
HU217841B (hu) * 1993-12-17 2000-04-28 The Procter & Gamble Co. 6-[(2-Imidazolidinilidén)-amino]-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) † 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5916900A (en) * 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
WO1999026942A1 (en) 1997-11-24 1999-06-03 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
MXPA02012206A (es) 2000-07-14 2003-06-04 Allergan Inc Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
PT2320911E (pt) * 2008-08-01 2014-11-11 Eye Therapies Llc Composições de vasoconstrição e métodos de utilização
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20180369240A1 (en) * 2008-08-01 2018-12-27 Eye Therapies Llc Preferential Vasoconstriction Compositions and Methods of Use
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
EP2329849B1 (de) 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
KR20130010122A (ko) 2010-03-26 2013-01-25 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
AU2011237689A1 (en) 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
AU2011237677A1 (en) 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
CA2807084C (en) 2010-07-29 2018-05-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

Also Published As

Publication number Publication date
JP2999240B2 (ja) 2000-01-17
US5021416A (en) 1991-06-04
ATE122233T1 (de) 1995-05-15
IL96083A0 (en) 1991-07-18
EP0426390B1 (de) 1995-05-10
AU627626B2 (en) 1992-08-27
TW218352B (de) 1994-01-01
KR910007530A (ko) 1991-05-30
HUT57045A (en) 1991-11-28
CA2025189A1 (en) 1991-05-01
RU1829937C (ru) 1993-07-23
NZ235884A (en) 1997-08-22
JPH03153626A (ja) 1991-07-01
HU207946B (en) 1993-07-28
DE69019297T2 (de) 1995-10-12
DE69019297D1 (de) 1995-06-14
HU906934D0 (en) 1991-05-28
IE903896A1 (en) 1991-05-08
EP0426390A3 (en) 1992-03-04
ES2074138T3 (es) 1995-09-01
PH26978A (en) 1992-12-28
IE68413B1 (en) 1996-06-12
AU6396690A (en) 1991-05-09
EP0426390A2 (de) 1991-05-08
IL96083A (en) 1997-06-10
FI905369A0 (fi) 1990-10-30

Similar Documents

Publication Publication Date Title
AU627626B2 (en) Method for using (2-imidazolin-2-ylamino)quinoxalines to reduce or maintain intraocular pressure
AU628666B2 (en) (2-imidazolin-2-ylamino) tetrahydro-quinoxalines and methods for using same
US5075323A (en) Compounds including omeprazole in the treatment of glaucoma
CA2240136A1 (en) Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
EP0218999A3 (en) New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them
CA2282890A1 (en) Therapeutic heterocyclic compounds
EP0389995A3 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie
KR940019701A (ko) N-헤테로아릴-n'-페닐우레아 유도체, 그의 제조방법 및 용도
HUT65574A (en) Process for preparing 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and pharmaceutical compositions containing them
HU9301197D0 (en) Medical preparatives containing quinoline and quinazoline derivatives as well as new quinoline and quinazoline derivatives
ES8506652A1 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
ES8605493A1 (es) Un procedimiento para la preparacion de un derivado de acido 2-anilino, 6,1-dihidro-6-oxo-5-pirimidincarboxilico.
IE893956L (en) Novel compounds
ES8702390A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,5-benzotiazepina
GR3001195T3 (en) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
AU6599186A (en) N-(6-(4-0-hydrxyphenyl-1,3-dioxan-cis-5-yl)hexenoyl) suphonamide derivatives
ES8401952A1 (es) Un procedimiento para preparar nuevos derivados de 1,4-benzotiazina.
IL109750A0 (en) Substituted 2-hydroxy-3-[1-(1h-imidazol-4-yl) alkyl]-benzenecarboximidamides, their preparation and ophthalmic compositions containing them
HUT45062A (en) Process for producing 1-hydroxy-5-oxo-5h-pindo/3,2-a/ phenoxazine-3-carboxylic acid esters and pharmaceuticals comprising the same as active ingredient